Drugs During Pregnancy

  title={Drugs During Pregnancy},
  author={R. Sannerstedt and P. Lundborg and B. Danielsson and I. Kihlstr{\"o}m and G. Alv{\'a}n and B. Prame and E. Ridley},
  journal={Drug Safety},
SummaryThe Swedish system for the classification of fetal risk of drugs was the first of its kind and was implemented in 1978. Drugs for use in pregnant women are classified in 4 general categories — A to D. The US Food and Drug Administration (FDA) introduced a system in 1979 also using the letters A to D, together with an X category. However, the definitions differ considerably between the FDA system and the Swedish system, resulting in a very different allocation of drugs to the respective… Expand
Risk Classification Systems for Drug Use During Pregnancy
Differences in category allocation for the same drug can be a source of great confusion among users of the classification systems as well as for those who require information regarding risk for drug use during pregnancy, and may limit the usefulness and reliability of risk classification systems. Expand
Prescription of Hazardous Drugs During Pregnancy
The use of hazardous prescription drugs declines during pregnancy but prescriptions of known teratogens and the relatively frequent practice of polypharmacy in epilepsy place emphasis on the need for careful pre-pregnancy counselling. Expand
Advice on Drug Safety in Pregnancy
The results of this study show considerable differences between two Norwegian sources providing advice on the use of drugs in pregnancy, and believe that the problem with heterogeneous drug information on this subject is not confined to Norway and that the results should be of international interest. Expand
Review of pregnancy labeling of prescription drugs: is the current system adequate to inform of risks?
The difficulties that are associated with the assessment of the benefits/risks of drug therapy during pregnancy are outlined, the history of the Food and drug Administration regulations for labeling prescription drugs, and the strengths and weaknesses of the current Food and Drug Administration pregnancy labeling system are reviewed. Expand
Prescription drug use in pregnancy: a retrospective, population-based study in British Columbia, Canada (2001-2006).
The prevalence of maternal prescription drug use emphasizes the need for postmarketing evaluation of the risk-benefit profiles of pharmaceuticals in pregnancy, and future research on prenatal drug use based on administrative databases should examine maternal treatment adherence and the determinants of maternal drug use. Expand
FDA Labeling System for Drugs in Pregnancy
The proposed pregnancy labeling system strives for more clinical usefulness by reliance on human data derived from pregnancy registries, and the clinical usefulness of the new labeling remains to be seen. Expand
The Use of Nonhuman Primates in Evaluating the Safety of Therapeutic Medications Used During Pregnancy
Publisher Summary This chapter focuses on the safety of drugs used to treat major diseases in pregnant women and reviews data on the reproductive and developmental consequences of therapeutic drugExpand
Use of Nimesulide During Early Pregnancy and the Risk of Congenital Malformations: A Population-Based Study from Italy
This study suggests that the use of nimesulide in early pregnancy may result in a greater risk of having births with congenital urinary tract anomalies. Expand
Clinicians' Perspective of The New Pregnancy and Lactation Labeling Final Rule (PLLR): Results from an AAAAI/FDA Survey.
The survey results suggest that the PLLR format was not known by a majority of prescribers and that the pregnancy letter category format is continuing to be used despite significant flaws in the old system. Expand
Patterns and determinants of prescribed drug use among pregnant women in Adigrat general hospital, northern Ethiopia: a cross-sectional study
The finding of this study revealed that a substantial proportion of pregnant women received drugs with potential harm to the mother and fetus, and notifying health practitioners to rely on up-to-date treatment guidelines strictly is highly demanded. Expand


Classification of drugs for teratogenic risk
The Teratology Society believes that the current FDA Usein-Pregnancy Ratings should be abandoned and recommends that drug labeling should include narrative statements that summarize and interpret available data regarding hazards of developmental toxicity and provide estimates of the teratogenic risk. Expand
Drug use During Pregnancy and Breast‐Feeding: A classification sytem for drug information
Since 1978 the Swedish catalogue of registered pharmaceutical specialities (FASS) has carried a special section entitled “Pregnancy and breast‐feeding” in each product presentation, intended to formExpand